Presentations by Program

Population pharmacokinetic (PPK), pharmacokinetic/pharmacodynamic attainment (PTA), clinical pharmacokinetic/pharmacodynamic (PK/PD) analyses for sulbactam-durlobactam (SUL-DUR) to support dose selection for the treatment of Acinetobacter baumannii–calcoaceticus complex (ABC) infections

Sujata Bhavnani, Christopher Rubino, Jeffrey Hammel, Anthony Cammarata, Kajal Larson, Sarah McLeod, Alita Miller, Paul Ambrose, Ruben Tommasi and John O'Donnell (IDWeek, 2022)

Efficacy of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with extensively drug-resistant (XDR) and pan-drug resistant (PDR) Acinetobacter baumannii-calcoaceticus complex (ABC) infections

Alita Miller, Sarah McLeod, Adam Shapiro, Khurram Rana, Drew Lewis, Gabrielle Poirier, Daria Chabas and David Altarac (IDWeek, 2022)

Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections

David Altarac, Alita Miller, Sarah McLeod, Adam Shapiro, Khurram Rana, Drew Lewis, Gabrielle Poirier, and Daria Chabas (IDWeek, 2022)

Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections: A detailed safety review from the pivotal phase 3, global, randomized, active-controlled trial (ATTACK)

Drew Lewis, Khurram Rana, Melissa Steidler, Gabrielle Poirier and David Altarac (IDWeek, 2022)

Efficacy and safety of sulbactam-durlobactam are consistent across regions in the global ATTACK phase 3 trial in the treatment of carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) infections

Alita Miller, Adam Shapiro, Sarah McLeod, Khurram Rana, Drew Lewis and David Altarac (IDWeek, 2022)

Characterization of colistin-resistant (COL-R) Acinetobacter baumannii-calcoaceticus complex (ABC) isolates from a recent global phase 3 trial (ATTACK)

Samir Moussa, Sarah McLeod and Alita Miller (IDWeek, 2022)

Pharmacokinetics/pharmacodynamics of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus Complex

John O'Donnell, Brian Van Scoy, Sujata Bhavnani, Paul Ambrose, Sarah McLeod and Ruben Tommasi (ASM Microbe, 2022)

In vitro activity of sulbactam-durlobactam in combination with other antimicrobial agents

Nicole Carter, Sarah McLeod, Adam Shapiro and Alita Miller (ASM Microbe, 2022)

Sulbactam-durlobactam is bactericidal against clinical isolates of Acinetobacter baumannii

Nicole Carter, Sarah McLeod, Adam Shapiro and Alita Miller (ASM Microbe, 2022)

ETX0462, a novel, non-β-lactam PBP inhibitor, has potent antibacterial activity against a panel of geographically diverse Gram-negative bacterial clinical isolates

John O'Donnell, Ramkumar Iyer, Thomas Durand-Reville, Ruben Tommasi, Stephen Hawser, Cyntia De Piano, Thomas Valmont, Ian Morrissey, Alita Miller (ASM Microbe, 2022)